Vivos Therapeutics Reports Widened $(21.23)M Net Loss for 2025, Revenue Up 16%
VVOS sits 25% above its 52-week low of $1.085 on elevated volume (2.3× avg).
Summary
Vivos Therapeutics reported its 2025 annual financial results via its 10-K, showing total revenue of $17.44 million, a 16% increase year-over-year. However, the company's net loss significantly widened to $(21.23) million, or $(2.07) per share, with operating loss also worsening to $(19.89) million. This critical financial update follows recent capital raising activities earlier this month, including a $2.39 million private placement and significant insider stock and warrant acquisitions. The substantial net loss, which is larger than the company's current market capitalization, indicates severe financial challenges and raises significant going concern risks. Despite revenue growth, the worsening profitability metrics and the fact that the Stanford clinical trial remains on hold are major negative signals for investors in this micro-cap company. Traders will closely monitor any further financing efforts, updates on the clinical trial, and management's plans to address the significant cash burn and improve the path to profitability.
At the time of this announcement, VVOS was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.4M. The 52-week trading range was $1.09 to $7.95. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.